Form 4: Liquidia CFO/COO Receives Significant Equity Grants

Liquidia Corp's CFO and COO, Michael Kaseta, was granted 59,320 Restricted Stock Units and 88,980 Performance Stock Units on January 16, 2026.

Summary

• Michael Kaseta, the Chief Financial Officer and Chief Operating Officer of Liquidia Corp (LQDA), received an equity grant on January 16, 2026.
• The grant included 59,320 Restricted Stock Units (RSUs) and 88,980 Performance Stock Units (PSUs).
• RSUs convert into common stock on a one-for-one basis, with 25% vesting on January 11, 2027, and 6.25% vesting every three months thereafter.
• PSUs also convert into common stock on a one-for-one basis, with 25% vesting on January 11, 2027 (or the FY2026 10-K filing date, if later), and 6.25% vesting every three months thereafter.
• PSU vesting is contingent upon achieving a milestone-based condition related to net product sales revenue from YUTREPIA in 2026, as disclosed in the Issuer's FY2026 10-K.
• Following these transactions, Michael Kaseta beneficially owns 410,239 shares of common stock, including previously granted unvested RSUs and shares acquired under the Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event. While the performance-based PSUs are a positive for aligning interests, the filing itself does not contain information that would significantly alter the company's fundamental outlook or financial performance in the immediate term, hence a neutral to slightly positive score.

Positives

• The equity grants, particularly the Performance Stock Units, align management's incentives directly with the company's performance, specifically YUTREPIA sales.
• The long-term vesting schedules for both RSUs and PSUs encourage executive retention and sustained focus on long-term shareholder value creation.
• The grants represent a standard form of executive compensation, indicating continued confidence in the executive team.

Negatives

• The vesting of a significant portion of the PSUs is tied to the performance of YUTREPIA sales in 2026, introducing a performance-based risk for the executive's compensation.
• The grants represent potential future dilution for existing shareholders as the units convert to common stock upon vesting.

Risks

• The vesting of 88,980 Performance Stock Units is contingent upon achieving specific net product sales revenue from YUTREPIA in 2026, as disclosed in the company's FY2026 10-K, introducing performance risk.
• Future stock dilution may occur as these RSUs and PSUs vest and convert into common stock.

Future Outlook

The grant of Performance Stock Units tied to 2026 YUTREPIA net product sales revenue indicates a strategic focus on the commercial success and revenue generation of this product in the near future.

Industry Context

Executive equity compensation, including Restricted Stock Units and Performance Stock Units, is a common practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key management personnel. Tying performance units to specific product sales milestones is a typical strategy to align executive compensation with critical commercial objectives.

Stakeholder Impact

• Shareholders: The grants align the CFO/COO's interests with shareholder value creation, particularly through the performance-based PSUs tied to YUTREPIA sales. However, there is potential for future dilution upon vesting.
• Employees: The grants are part of the company's executive compensation strategy, which can influence overall compensation philosophy and morale.

Next Steps

• The company will disclose its FY2026 10-K, which will include the net product sales revenue from YUTREPIA for 2026, a key condition for PSU vesting.
• The initial vesting of the newly granted RSUs and PSUs is scheduled for January 11, 2027.

Key Dates

Keywords

Liquidia Corp, LQDA, Michael Kaseta, CFO, COO, Form 4, RSU, PSU, equity grant, stock compensation, YUTREPIA, executive compensation